EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The GLP‐1 receptor agonist exenatide reduces serum TSH by its effect on body weight in people with type 2 diabetes

Su Ann Tee iD, Vasileios Tsatlidis, Salman Razvi iD

Clinical Endocrinology · 2023

DOI: 10.1111/cen.14901 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Endocrinology, 2023. Verfasst von Su Ann Tee und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Gateshead Health NHS Foundation Trust, Gateshead, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) therapy in patients with type 2 diabetes and obesity leads to a significant reduction in serum thyrotropin (TSH) levels but it is unclear whether this is related to weight loss and improvement in sensitivity to thyroid hormones (TH). Design, Patients and Measurements We prospectively analysed clinical and biochemical data in patients with type 2 diabetes and obesity who were commenced on the GLP‐1 RA exenatide and followed them for 12 months. We assessed the relationship between changes in body weight and serum TSH and resistance to TH indices.

Results

In 112 patients (mean age: 53.5 years, 43.8% female, mean body mass index: 39.8 kg/m 2 ), 12 months of exenatide treatment was associated with a mean (95% CI) percent body weight loss of 6.5% (5.0%−8.1%) and change in serum TSH of −0.25 mU/L (−0.43 to −0.06). There was a significant negative and nonlinear relationship between change in serum TSH and percent body weight loss: −0.25 mU/L with 5%, −0.4 mU/L with 10% and −0.5 mU/L with 15%, respectively, whereas a rise in serum TSH of 0.5 mU/L was associated with 5% weight gain. There were no changes observed in serum FT4 levels with weight loss but a significant reduction in resistance to TH indices was noted.

Conclusions

Exenatide therapy reduces serum TSH levels and improves central sensitivity to TH action over 12 months via its effect on weight loss. The effectiveness of weight loss strategies, rather than TH replacement, should be investigated in individuals with obesity and mildly raised serum TSH levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2HumansFemaleMiddle AgedMaleExenatideGlucagon-Like Peptide-1 ReceptorBody WeightObesityThyroid HormonesWeight LossGlucagon-Like Peptide 1ThyrotropinGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

TSHbody weightexenatidefree T4

Substanzen

ExenatideGlucagon-Like Peptide-1 ReceptorThyroid HormonesGlucagon-Like Peptide 1ThyrotropinGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Endocrinology, Gateshead Health NHS Foundation Trust, Gateshead, UK.
  • Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.

ORCID-Profile: Su Ann Tee, Salman Razvi

Zitieren

APA

Tee, S. A., Tsatlidis, V., & Razvi, S. (2023). The GLP‐1 receptor agonist exenatide reduces serum TSH by its effect on body weight in people with type 2 diabetes. Clinical Endocrinology. https://doi.org/10.1111/cen.14901

Vancouver

Tee SA, Tsatlidis V, Razvi S. The GLP‐1 receptor agonist exenatide reduces serum TSH by its effect on body weight in people with type 2 diabetes. Clinical Endocrinology. 2023. doi:10.1111/cen.14901

BibTeX
@article{Tee2023,
  author = {Tee, Su Ann and Tsatlidis, Vasileios and Razvi, Salman},
  title = {The GLP‐1 receptor agonist exenatide reduces serum TSH by its effect on body weight in people with type 2 diabetes},
  journal = {Clinical Endocrinology},
  year = {2023},
  doi = {10.1111/cen.14901}
}
Kostenlos starten →